We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Is this a better dividend stock than Royal Dutch Shell Plc after today’s results?

Should you buy this company for its income appeal instead of Royal Dutch Shell Plc (LON: RDSB)?

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Leading primary care property investor Assura (LSE: AGR) has released an upbeat trading update for the first half of the year. It provides clues as to whether it is a high quality income stock, as well as if it is a superior dividend play to popular income stock Shell (LSE: RDSB).

Assura has made multiple acquisitions during the period. It has completed the purchase of 41 medical centres for a gross consideration of £81m. They have a passing rent roll of £4.9m and a weighted average unexpired lease length of 13.5 years, which improves Assura’s long term profit outlook. Its pipeline of individual asset acquisitions and developments currently in solicitor’s hands are worth £114m, providing evidence of the growth potential of the company over the medium term.

Should you buy Assura Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

In fact, Assura now owns 363 medical centres, with a total annualised rent roll of £70m. Its growth has been driven mostly by the aforementioned acquisitions, but its income is also being maximised by active asset management. Its financial outlook has also been improved by new borrowing facilities, as well as a reduction in the weighted average cost of debt. This has fallen from 4.84% at 31 March 2016 to 4.3%, while its proforma net loan to value ratio is 36%. This is below the medium term loan-to-value (LTV) range of 40-50%.

Assura is still seeking a new CEO and it announced today that its CFO will work as interim CEO. This adds an element of risk to Assura’s outlook, since a new CEO could change the company’s strategy. However, in terms of Assura’s income prospects, it has considerable appeal. It yields 3.9% and has an excellent track record of dividend growth. For example, in the last four years dividends have increased in each year at an annualised rate of 19.6%. Given its potentially bright future, further brisk dividend growth could lie ahead.

However, the dividend growth available elsewhere may be even more impressive. Shell’s combination with BG is set to yield greater synergies than previously thought and the merged asset base of the two companies is forecast to generate significantly higher free cash flow than at the present time. This should allow Shell to not only invest in its asset base, but to also pay a much higher dividend than is the case. And with it currently yielding 7.2%, Shell offers a high yield to begin with. When combined with its dividend growth potential, this makes it a top notch income stock.

Of course, the outlook for the oil price is still highly uncertain. In this respect, Shell is a higher risk option than Assura. Further falls in the price of oil cannot be ruled out. But with Shell assuming an oil price of $60 over the medium term, its forecasts are built on relatively conservative assumptions. This potential for dividend growth as well as its significantly higher yield mean that it is a better income option than Assura at the present time.

Peter Stephens owns shares of Royal Dutch Shell B. The Motley Fool UK has recommended Royal Dutch Shell B. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A row of satellite radars at night
Investing Articles

This ex-penny stock has crushed Rolls-Royce shares over 5 years! Is there more to come?

With all eyes on Rolls-Royce shares, this growth share with a connection to SpaceX might have gone unnoticed by a…

Read more »

Close-up as a woman counts out modern British banknotes.
Investing Articles

With a 6.4% yield and P/E of 10 is this FTSE dividend stock a hidden passive income gem?

Building a portfolio of solid UK dividend stocks isn't hard. Paul Summers takes a closer look at one high-yielding candidate…

Read more »

Black woman using smartphone at home, watching stock charts.
Growth Shares

At 112p, where next for the Lloyds share price? 168p or 56p?

Jon Smith mulls over the direction going forward for the Lloyds share price, and explains why two very different scenarios…

Read more »

Investing Articles

This dividend stock has a 7.3% yield, and Stocks and Shares ISA investors are buying!

Looking to move from a Cash ISA to a Stocks and Shares ISA to target passive income? Alan Oscroft has…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

Could Rolls-Royce shares lock in another 34% gain before Christmas?

Mark Hartley takes a look at some of the more optimistic price targets for Rolls-Royce, and considers a best-case scenario.…

Read more »

This way, That way, The other way - pointing in different directions
Investing Articles

Investec vs Aberdeen: which is the better income stock to buy?

Aiming to boost the average yield of his income portfolio, Mark Hartley's looking for new income stocks to buy on…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

Down 41% since January, this quality S&P 500 stock is stinking out my ISA

The tide's turned against this S&P 500 robotics stock. Is it time to dump it? Or is there a no-brainer…

Read more »

GSK scientist holding lab syringe
Investing Articles

By mid-2027, analysts expect £6,000 in GSK shares to be worth…

GSK shares are currently trading almost 20% below their 2026 highs. Is there potential for a rebound over the next…

Read more »